Sign in
AMGN-AMGEN INC

Amgen Reports Strong Q4 Earnings with $9.1 Billion in Revenue, Surpassing Expectations Amid Regulatory Challenges

Saturday

15 February, 2025

Amgen's fourth-quarter results reveal a remarkable $9.1 billion in revenue and a 14% increase in product volume, showcasing its resilience amid regulatory hurdles. With a strong pipeline and a commitment to innovation, can Amgen navigate its challenges and continue to deliver value to shareholders?

article image for AMGN

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
70
Key Takeaways
  • Amgen reported strong Q4 results with significant earnings and revenue growth, highlighting its market potential.
  • The company boasts a promising pipeline in oncology and rare diseases, featuring numerous billion-dollar products.
  • Amgen's acquisition of Horizon Therapeutics strengthens its position in the rare disease market.
  • A notable dividend increase over the last decade reflects Amgen's dedication to shareholder returns.
  • Recent earnings trends suggest a favorable investment opportunity for those interested in biotechnology growth.
More on AMGEN INC
Read more insights on AMGEN INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.